Combination treatment of depression.

Combination treatment of depression.

Detalhes bibliográficos
Main Authors:	Cowen, P, Power, A
Formato:	Journal article
Idioma:	English
Publicado em:	1993

Registos relacionados

Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression.
Por: Power, A, et al.
Publicado em: (1992)

Effect of pharmacologic treatments on the sleep of depressed patients.
Por: Sharpley, A, et al.
Publicado em: (1995)

Drug treatment of tricyclic resistant depression
Por: Chalmers, J, et al.
Publicado em: (1990)

Behavioral Neurobiology of Depression and Its Treatment
Por: Cowen, P, et al.
Publicado em: (2013)

5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone.
Por: Cowen, P, et al.
Publicado em: (1994)

ANTI-DEPRESSANT TREATMENT AND BETA-ADRENOCEPTOR FUNCTION IN THE RAT PINEAL
Por: Cowen, P, et al.
Publicado em: (1981)

Depression in the elderly.
Por: Cowen, P
Publicado em: (1994)

Classification of depressive disorders.
Por: Cowen, P
Publicado em: (2013)

Biological markers in depression
Por: Cowen, P
Publicado em: (1989)

Neural effects of 7-day anti-depressant treatment on reward
Por: Mccabe, C, et al.
Publicado em: (2009)

The potential use of ebselen in treatment-resistant depression
Por: Ramli, FF, et al.
Publicado em: (2022)

Biological markers of depression.
Por: Cowen, P, et al.
Publicado em: (1991)

Depression resistant to tricyclic antidepressants.
Por: Cowen, P
Publicado em: (1988)

Depression resistant to tricyclic antidepressants.
Por: Cowen, P
Publicado em: (1988)

Serotonin, depression and antidepressant action
Por: Cowen, P
Publicado em: (2013)

Back to the future: the neurobiology of major depression.
Por: Cowen, P
Publicado em: (1998)

Fluoxetine improves minor depressive disorders.
Por: Cowen, P
Publicado em: (2005)

Not fade away: the HPA axis and depression.
Por: Cowen, P
Publicado em: (2010)

Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression?
Por: Rabiner, E, et al.
Publicado em: (2004)

Recent views on the role of 5-hydroxytryptamine in depression
Por: Cowen, P
Publicado em: (1988)

ABNORMAL 5-HT NEUROENDOCRINE FUNCTION IN DEPRESSION
Por: Cowen, P
Publicado em: (1990)

Serotonin and depression: pathophysiological mechanism or marketing myth?
Por: Cowen, P
Publicado em: (2008)

The Potential Use of Ebselen in Treatment-Resistant Depression
Por: Fitri Fareez Ramli, et al.
Publicado em: (2022-04-01)

Systematic review of pindolol augmentation of serotonergic antidepressant treatment for major depressive disorder
Por: Whale, R, et al.
Publicado em: (2005)

Fluoxetine and suicidal behaviour. Some clinical and theoretical aspects of a controversy.
Por: Power, A, et al.
Publicado em: (1992)

Predicting treatment response in depression: the role of anterior cingulate cortex
Por: Godlewska, BR, et al.
Publicado em: (2018)

Backing into the future: pharmacological approaches to the management of resistant depression
Por: Cowen, P
Publicado em: (2017)

Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.
Por: Godlewska, B, et al.
Publicado em: (2012)

Short-term SSRI treatment remediates amygdala hyperactivity in depressed patients
Por: Godlewska, B, et al.
Publicado em: (2011)

Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment.
Por: Cowen, P, et al.
Publicado em: (1987)

5-HT and depression: is the glass half-full?
Por: Sharp, T, et al.
Publicado em: (2011)

Using neuroimaging to identify neural markers of familial vulnerability to depression
Por: Cowen, P
Publicado em: (2014)

What has serotonin to do with depression?
Por: Cowen, P, et al.
Publicado em: (2015)

Frontal cortex stimulation reduces vigilance to threat: Implications for the treatment of depression and anxiety
Por: Ironside, M, et al.
Publicado em: (2016)

Fifty years on: serotonin and depression
Por: Jauhar, S, et al.
Publicado em: (2023)

Efficacy markers in depression
Por: Harmer, C, et al.
Publicado em: (2011)

Efficacy markers in depression.
Por: Harmer, C, et al.
Publicado em: (2011)

Imaging vulnerability for depression
Por: Norbury, R, et al.
Publicado em: (2011)

Imaging vulnerability for depression.
Por: Norbury, R, et al.
Publicado em: (2011)

Tryptophan and depression - Reply
Por: Smith, K, et al.
Publicado em: (1997)